Inoviv provides end‑to‑end targeted proteomics services for pharma and biotech companies, delivering pre‑validated or custom multiplexed LC‑MS biomarker panels that quantify proteins, PTMs, lipids, and metabolites with absolute accuracy down to pg/mL. Their CLIA‑ and GLP‑certified workflow includes sample preparation, proprietary standards, high‑throughput LC‑MS/MS analysis, and bioinformatics reporting, enabling rapid biomarker validation, treatment monitoring, patient stratification, and companion diagnostic development.
Funding
$8.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HVFounders
Product
Problem
Pharmaceutical and biotech companies often lack rapid, highly quantitative proteomics assays that can reliably measure multiple low-abundance biomarkers across diverse sample types, leading to delayed biomarker validation, higher clinical trial risk, and limited insight into drug mechanism of action.
Solution
Inoviv offers end‑to‑end targeted proteomics services that combine pre‑validated or custom multiplexed LC‑MS panels with CLIA‑ and GLP‑certified laboratories. Their workflows provide absolute quantification from pg/mL to ng/mL with high reproducibility (CV < 10%) and a linear dynamic range spanning six orders of magnitude. Clients receive fully calibrated, cross‑reactivity‑free assays for proteins, PTMs, lipids, and metabolites, along with bioinformatics analysis and interpretation. Results are delivered within 2–4 months in a concise report that links biomarker data to disease biology, enabling treatment monitoring, patient stratification, and companion diagnostic development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapeutics who need quantitative biomarker panels for drug discovery, clinical trial monitoring, patient stratification, and companion diagnostic development.
Features
- Pre‑validated panels measuring 50+ biomarkers per run with no cross‑reactivity
- Custom assay design, rapid development, and regulatory‑grade validation
- Immunoprecipitation‑MS (IP‑MS) for ultra‑low pg/mL quantification in a 10‑minute multiplexed run
- Support for multiple matrices (plasma, serum, CSF, urine, tissue, FFPE, cell lysates)
- High‑throughput LC‑MS/MS platforms in US CLIA‑certified and UK GLP‑accredited labs
- Full data pipeline: sample prep, proprietary standards, DIA/DIA‑based discovery, MRM quantification, and bioinformatics reporting
- End‑to‑end service from biomarker selection through data interpretation and regulatory submission support